pasw software (predictive analytics software; v 21 (SPSS Inc)
SPSS Inc is a verified supplier 
90
Structured Review
SPSS Inc
pasw software (predictive analytics software; v 21
Pasw Software (Predictive Analytics Software; V 21, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pasw+software+(predictive+analytics+software%3B+v+21/pasw+statistics+18/pm35768316-59-1-9
Average 90 stars, based on 1 article reviews
Pasw Software (Predictive Analytics Software; V 21, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pasw+software+(predictive+analytics+software%3B+v+21/pasw+statistics+18/pm35768316-59-1-9
Average 90 stars, based on 1 article reviews
pasw software (predictive analytics software; v 21 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Software:Article Title: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Article Snippet: Background Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC).. However, few clinical data are available regarding the efficacy of cabozantinib following immunotherapy.. Objective To describe the outcome of cabozantinib in patients previously treated with immunotherapy. Article Title: ABSTRACTS OF THE 31st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO): 30 September - 2 October 2021, Virtual Meeting. Article Snippet: .. The Article Title: Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Article Snippet: Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib Roberto Iacovelli, 1 Chiara Ciccarese, 1 , 2 Marco Maruzzo, 3 Francesco Atzori, 4 Luca Galli, 5 Sarah Scagliarini, 6 Francesco Massari, 7 Elena Verzoni, 8 Antonella Cannella, 1 Maria Grazia Maratta, 1 Claudia Caserta, 9 Davide Bimbatti, 3 Filippo Maria Deppieri, 3 Mariele Dessi, 4 Federico Paolieri, 5 Ferdinando Riccardi, 6 Sergio Bracarda, 9 Ugo De Giorgi, 10 Umberto Basso, 3 Giampaolo Tortora, 1 , 2 , # Article Title: Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Article Snippet: Objectives: To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced firstline dose of sunitinib or pazopanib compared to those who continue at the standard dose.. Patients and methods: All the patients treated in 11 oncological centers in Italy for mRCC who started first-line treatment with sunitinib or pazopanib at the standard dose.. Descriptive statistical tests were used to highlight differences among groups. Article Title: Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Article Snippet: Davide Bimbatti, M.D., Chiara Ciccarese, M.D., Emanuela Fantinel, M.D., Teodoro Sava, M.D., Francesco Massari, M.D., Iolanda Bisogno, Mario Romano, M.D., Antonio Porcaro, M.D., Matteo Brunelli, Prof., Guido Martignoni, Prof., Renzo Mazzarotto, M.D., Walter Artibani, Prof., Giampaolo Tortora, Prof., Roberto Iacovelli, Ph.D.* Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Department of Oncology, Camposampiero-Cittadella, Padua, Italy Division of Oncology, Sant’Orsola-Malpighi Hospital, Bologna, Italy Radiotherapy Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Urology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Department of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata, Verona, Italy U.O.C.. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy |